In glioma, high SFRP4 expression is strongly associated with poor outcomes (HR = 3.93 [2.27–6.81], p < 0.0001), while high SFRP2 expression is strongly associated with favourable outcomes (HR = 0.16 [0.09–0.28], p < 0.0001). The gene discussed is SFRP2; the disease is central nervous system cancer.